Supernus Q2 2023 revenues $135.5M, down 20% YoY; GAAP operating loss $17.6M

SUPERNUS PHARMACEUTICALS, INC.

2023-Q2 EPS reported $0.29 revenue$289,327,000

Qelbree net sales $31.0M (+179%), GOCOVRI $28.8M (+17%) in Q2 2023 vs Q2 2022.
Trokendi XR net sales fell 73% in Q2 and 60% in H1 2023 due to generic erosion.
GAAP net loss ($0.8M) or ($0.02)/diluted share; adjusted operating earnings $10.0M vs $37.6M.
Cash & securities $189.1M at June 30, 2023, down from $555.2M due to $402.5M note repayment.
Full-year 2023 guidance reaffirmed: total revenue $580-$620M, GAAP operating loss $(30)-$(10)M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.